M1- and M2-Type Macrophage Responses Are Predictive of Adverse Outcomes in Human Atherosclerosis

Monica de Gaetano1, Daniel Crean2, Mary Barry3

  • 1School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin , Dublin , Ireland.

Insights

Macrophages in atherosclerosis exhibit dual roles. Pro-inflammatory MΦ1 markers increase in symptomatic plaques, while anti-inflammatory MΦ2 markers correlate with disease stability, offering insights into atherosclerotic progression.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Pathogenesis of Atherosclerosis

Background:

  • Atherosclerosis is a chronic inflammatory disease involving endothelial injury, lipid deposition, and oxidative stress, leading to plaque rupture and thrombosis.
  • Macrophages play a critical role in atherosclerosis by regulating lipid metabolism and sustaining inflammation.
  • Macrophages are heterogeneous, with MΦ1 (pro-inflammatory) and MΦ2 (anti-inflammatory) phenotypes potentially shifting during disease progression.

Purpose of the Study:

  • To investigate the changes in macrophage subpopulations within human atherosclerotic plaques during disease progression.
  • To correlate the presence and phenotype of macrophages with the clinical presentation (symptomatic vs. asymptomatic) of atherosclerosis.

Main Methods:

  • Histological and immunohistochemical analyses of atherosclerotic plaques from patients undergoing carotid endarterectomy.
  • Quantification of cellular content and macrophage subsets (MΦ1 and MΦ2 markers).
  • Real-time PCR and Western blot analysis to assess gene and protein expression of MΦ1/MΦ2 markers and associated cytokines.

Main Results:

  • Symptomatic plaques exhibited increased hemorrhagic activity and a higher prevalence of fibrotic, necrotic tissue, and calcifications.
  • Both MΦ1 and MΦ2 macrophages were present, with MΦ2 macrophages localized to more stable plaque regions.
  • MΦ1 markers and Th1 cytokines were highly expressed in symptomatic plaques, whereas MΦ2 markers (MR, CD163) and Th2 cytokines showed an inverse relationship with disease progression.

Conclusions:

  • Macrophage phenotype switching is implicated in atherosclerosis progression.
  • MΦ1 macrophages are associated with symptomatic, unstable plaques, while MΦ2 macrophages may contribute to plaque stability.
  • Understanding macrophage dynamics in atherosclerotic lesions provides crucial insights into disease pathogenesis and potential therapeutic targets.

Related Concept Videos

Inflammation01:38

Inflammation

Overview
63.8K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.8K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
879
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
564